Table 1.

Currently available antifungal agents for the treatment of candidemia.

Name	Class	Mechanism of action	Company	FDA approved indications
Fluconazole	Antifungal triazole	Inhibitor of lanosterol 14α-demethylase, leading to inhibition of ergosterol biosynthesis	Pfizer / various	Treatment of candidemia, disseminated candidiasis, and pneumonia, as well as Candida urinary tract infections, peritonitis, oropharyngeal and esophageal candidiasis. Prophylaxis of candidiasis in patients undergoing bone marrow transplantation.
Voriconazole	Antifungal triazole		Pfizer / various	Candidemia (nonneutropenic patients) and disseminated candidiasis in skin, abdomen, kidney, bladder wall, wounds, esophageal candidiasis.
Anidulafungin	Echinocandin	Inhibitor of (1→3)-β-D-glucan synthase	Pfizer	Candidemia, Candida intra-abdominal abscess and peritonitis, esophageal candidiasis.
Caspofungin	Echinocandin		Merck	Treatment of candidemia, Candida intra-abdominal abscess and peritonitis, pleural space infection, esophageal candidiasis. Empirical therapy for presumed fungal infections in febrile neutropenia.
Micafungin	Echinocandin		Astellas Pharma US Inc.	Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscess, esophageal candidiasis. Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Amphotericin B deoxycholate	Polyene	Binds ergosterol in the cell membrane leading to changes in membrane permeability	X-GEN Pharmaceuticals Inc.	Treatment of invasive infections due to Candida species.
Amphotericin B lipid complex	Polyene		Sigma-Tau Pharmaceuticals Inc.	Treatment of invasive fungal infections in patients who are refractory to or intolerant to amphotericin B deoxycholate.
Liposomal amphotericin B	Polyene		Astellas Pharma US Inc.	Treatment of patients with Candida species infections refractory to amphotericin B deoxycholate or in patients with renal impairment. Empirical therapy for presumed fungal infection in febrile neutropenia.